Clinical Trials Logo

Polycystic Liver Disease clinical trials

View clinical trials related to Polycystic Liver Disease.

Filter by:

NCT ID: NCT01315795 Completed - Clinical trials for Polycystic Liver Disease

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

LOCKCYST
Start date: March 2011
Phase: Phase 2/Phase 3
Study type: Interventional

An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.

NCT ID: NCT01157858 Completed - Clinical trials for Polycystic Liver Disease

Everolimus and LongActing Octreotide Trial in Polycystic Livers

ELATE
Start date: June 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to reduce polycystic liver volume by treating with octreotide, whether or not combined with everolimus; to assess whether combination therapy of everolimus and octreotide gives a bigger reduction of polycystic liver volume than octreotide monotherapy.

NCT ID: NCT00934791 Terminated - Clinical trials for Polycystic Liver Disease

Polycystic Liver Disease in Kidney Transplant

Start date: February 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are the two immunosuppressive drugs that will be compared for this study. Both drugs have been commonly prescribed to prevent rejection.

NCT ID: NCT00771888 Active, not recruiting - Liver Diseases Clinical Trials

Open-Label Extension of LOCKCYST Trial

LOCKCYST-ext
Start date: April 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available. Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

NCT ID: NCT00565097 Completed - Liver Diseases Clinical Trials

Lanreotide as Treatment of Polycystic Livers

LOCKCYST
Start date: October 2007
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

NCT ID: NCT00426153 Completed - Liver Diseases Clinical Trials

Octreotide in Severe Polycystic Liver Disease

Start date: January 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence indicates that this drug is safe and non-toxic in other disease states. Treatment with this drug holds promise not only for individuals with liver involvement, but also for many more patients with polycystic kidney disease.